VA-DXC-TECHNOLOGY
18.3.2020 14:02:17 CET | Business Wire | Press release
DXC Technology (NYSE: DXC) today introduced an advanced Patient-Centered Care solution, a customizable and personalized-health offering that gives healthcare providers the technology to meet the high expectations of today’s patients — without sacrificing cost containment and clinician satisfaction.
The healthcare industry is experiencing a value-based shift of epic proportions, driven by key external trends like an aging population; the proliferation of chronic diseases; rising healthcare costs; staffing shortages; and digital citizenship creating more informed patients. To elevate the patient experience, improve individual outcomes and create a healthier population, healthcare leaders are seeking new business and integrated care models that merge healthcare and life sciences while empowering patients and providers alike.
To help solve these challenges, DXC Patient-Centered Care provides advanced patient-engagement tools that offer convenient care from anywhere, via phone or tablet, at an affordable price. Backed by DXC’s interoperability, analytics and security products, the solution enables providers to access a continuous stream of patient-care data, helping them put the patient first throughout the continuum of care.
“In the age of ‘Dr. Google’ and same-day Amazon deliveries, patients are increasingly more demanding. They will no longer tolerate half-day waits for discharge instructions that could be delivered in seconds via a chatbot, or receive test results by snail mail when they could be viewed immediately on a mobile app. They expect better value and engagement from caregivers, driving the industry to move from traditional care-delivery models toward a patient-centered journey of care,” said Andrea Fiumicelli, vice president and general manager, Healthcare and Life Sciences , DXC Technology. “Our new Patient-Centered Care solution combines DXC’s industry expertise and leading healthcare technology to equip providers with custom-built, next-generation and coordinated care solutions.”
“The future of connected healthcare is centered around collaboration and care, and today’s busy providers need to find innovative ways to connect with their patients within and beyond the walls of a hospital or clinic,” said Dr. Michael Dahlweid, who recently joined DXC as its new global chief medical officer. “Our goal is to enable care teams to share health information across multiple systems, channels, practices and infrastructures, and aggregate it into a secure, consolidated view of the patient’s history of care. This persona-based access to real-time health data will allow clinicians to make the best possible decisions for their patients’ treatment. With speed, scale, flexibility and continuous innovation, DXC Technology prepares traditional healthcare organizations to become major digital-health enablers.”
The DXC Healthcare Portfolio
Patient-Centered Care is the newest solution in DXC’s extensive healthcare portfolio that is transforming the healthcare industry. The portfolio also includes:
- DXC Open Health Connect , a healthcare platform that helps improve healthcare outcomes by creating a connected ecosystem for patients, providers and payers.
- DXC Healthcare Cloud , a cloud-based solution that reduces complexity and risk while allowing approved parties to securely access applications and data 24/7.
- DXC Healthcare Security Services — for which DXC was recently named a leader in the Everest Group PEAK Matrix Assessment 2020 — to help healthcare providers quickly identify and respond to threats, protect data and patient privacy, and securely manage patient identities stored on-premise or in the cloud.
- DXC Health360 ™ , a cloud-based solution that enables providers and payers to personalize care experiences, deliver quality and increase customer loyalty at a lower cost.
- DXC Life Sciences solutions , which give life sciences organizations — including all 12 U.S. Fortune 500 pharmaceutical companies — the tools they need to accelerate innovation, improve operational efficiencies and reduce time to market for new therapies, devices and medicines.
About DXC Technology
DXC Technology (NYSE: DXC) helps global companies run their mission critical systems and operations while modernizing IT, optimizing data architectures, and ensuring security and scalability across public, private and hybrid clouds. With decades of driving innovation, the world’s largest companies trust DXC to deploy our enterprise technology stack to deliver new levels of performance, competitiveness and customer experiences. Learn more about the DXC story and our focus on people, customers and operational execution at www.dxc.technology .
# # #
View source version on businesswire.com: https://www.businesswire.com/news/home/20200318005372/en/
Link:
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
AB InBev Reports Full Year and Fourth Quarter 2025 Results12.2.2026 07:01:00 CET | Press release
Underlying EPS increased by 6% with continued margin expansion and free cash flow generation of 11.3 billion USD Anheuser-Busch InBev (Brussel:ABI) (BMV:ANB) (JSE:ANH) (NYSE:BUD): This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260211688662/en/ Figure 14. Terms and debt repayment schedule as of 31 December 2025 (billion USD) Regulated and inside information1 “Beer plays an important role in bringing people together and creating moments of celebration. In 2025, we executed our strategy, made disciplined capital allocation choices and delivered growth within our outlook for the year, even as we navigated a dynamic consumer environment. We exit 2025 with improved momentum and enter 2026 well positioned to engage consumers with our megabrands and an unparalleled lineup of mega platforms. Thank you to our colleagues for their ongoing commitment, hard work and passion for our business.” – Michel Doukeris, CEO, AB InBev Revenue 4Q +
Bardasz Forms Strategic Digital Alliance with GEOLOG to Accelerate Global RTOC Delivery and Digital Well Construction Solutions12.2.2026 07:00:00 CET | Press release
HighlightsBardasz and GEOLOG form an alliance to strengthen delivery of end-to-end RTOC solutions for drilling optimization and NPT mitigation.Alliance combines Bardasz’s leadership in WITSML and ETP transmission, high-speed real-time data aggregation, and Super Store technology with GEOLOG’s global operational scale and local technical workforce.As part of the alliance, GEOLOG has made a minority investment in Bardasz, providing financial flexibility to accelerate Bardasz’s product roadmap and global expansion. Bardasz Group LLC (“Bardasz”), a provider of real-time, decision-ready intelligence for well construction—including drilling, completions, and well interventions—today announced a strategic digital alliance with GEOLOG International B.V. (“GEOLOG”), a global formation evaluation, drilling, and geochemistry services provider supporting subsurface projects in more than 40 countries. The alliance is designed to accelerate Bardasz’s global growth and enhance customer delivery by le
We Are All Sculptra: First-of-its-Kind Galderma Initiative to Demonstrate How Everyone Can Benefit from Sculptra’s Regenerative Properties12.2.2026 07:00:00 CET | Press release
Galderma unveils We Are All Sculptra, a global campaign capturing the clinical performance of Sculptra® across nine diverse patient profiles and journeys, over two years1 Backed by over 25 years of clinical use, Sculptra continues to prove its versatility as a regenerative treatment that works across all three layers of the skin2-6 The campaign captures the patients’ clinical and emotional experiences – including before & after treatment imagery – highlighting Sculptra’s adaptability and reinforcing its role in tailored, science-backed regenerative aesthetic care1 Galderma (SIX: GALD), the pure-play dermatology category leader, today unveiled We Are All Sculptra, a unique program designed to capture the clinical impact of Sculptra® across nine diverse patients – who were all new to injectable aesthetics – over two years.1 This innovative initiative will offer a rare and authentic real-life perspective on the power of regenerative biostimulation to deliver personalized outcomes, and dem
Lenovo Group: Third Quarter Financial Results 2025/2612.2.2026 05:13:00 CET | Press release
Lenovo delivers exceptional quarter, marks era of accelerated AI-driven growth and profitability Lenovo GroupLimited (HKSE: 992) (ADR: LNVGY), together with its subsidiaries (‘the Group’), today reported results for the third quarter of fiscal year 2025/26, a quarter that delivered record revenues, accelerated profitability, and continued AI revenue expansion. During the quarter, overall group revenue reached an all-time fiscal quarter high of US$22.2 billion, up 18% year-on-year, with revenue from all business groups growing double-digit year-on-year. Excluding non-operating non-cash items and one-time gains and charges in Q3 FY24/25 and Q3 FY25/26, adjusted net income (profit attributable to equity holders – non-HKFRS)[1] increased by 36% year-on-year to US$589 million, with adjusted net income margin[1] expanding to 2.7%. The results demonstrate the Group’s ability to deliver on its promise of double-digit growth and sustained profitability, while proving its ability to manage throu
IFF Reports Fourth Quarter and Full Year 2025 Results11.2.2026 22:36:00 CET | Press release
Delivered solid top and bottom-line performance & advanced strategic priorities in 2025Launched sale process for the Food Ingredients segmentContinuing to drive financial performance in 2026 International Flavors & Fragrances Inc. (NYSE: IFF) reported financial results for the fourth quarter and full year ended December 31, 2025. Full year 2025 Consolidated Summary: Management Commentary “IFF delivered a solid 2025 performance, meeting the full-year financial commitments we set at the start of the year, despite a challenging operating environment,” said Erik Fyrwald, CEO of IFF. “It was also a year of continued strategic progress. We invested in R&D, commercial capabilities, and capacity expansion to better serve customers, advance our innovation pipeline, and support future profitable growth.” “We also took steps to optimize our portfolio. Through several divestitures and the recent launch of a sale process for our Food Ingredients segment, we sharpened our strategic focus and improve
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom
